Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Dr. Phyllis Billia, a UHN clinician-scientist at the Peter Munk Cardiac Centre has witnessed fruitful collaborations first-hand at the Ted Rogers Centre for Heart Research, where she’s working with scientists Craig Simmons and Anthony Gramolini in our Translational Biology and Engineering program.
With Gramolini, an expert in cardiovascular proteomics, she is aiming to discover new biomarkers in patients who have inherited cardiomyopathy. This is vital to understanding why heart failure develops and to detecting the progression of the disease in patients.
Her partnership with Simmons – an expert in tissue and biomedical engineering – resulted from a chance encounter at a Ted Rogers Centre event, where over lunch they started chatting about their respective research interests. It was soon clear to Dr. Billia that Simmons’ work with a microfluidic platform could help model heart disease in a dish.
Such an instrument is key to testing new therapies safely and efficiently – and is a major advance toward individualized heart failure treatment.
Dr. Billia co-manages an important biobank that the Ted Rogers Centre helps to fund.
